{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:44:26Z","timestamp":1760607866031},"reference-count":27,"publisher":"Elsevier BV","issue":"17-18","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1016\/s0264-410x(02)00102-0","type":"journal-article","created":{"date-parts":[[2002,10,15]],"date-time":"2002-10-15T14:10:16Z","timestamp":1034691016000},"page":"2343-2347","source":"Crossref","is-referenced-by-count":22,"title":["Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17\/p24:Ty virus-like particles on HIV-1 disease progression"],"prefix":"10.1016","volume":"20","author":[{"given":"Catharina E.A.","family":"Lindenburg","sequence":"first","affiliation":[]},{"given":"Ineke","family":"Stolte","sequence":"additional","affiliation":[]},{"given":"Miranda W.","family":"Langendam","sequence":"additional","affiliation":[]},{"given":"Frank","family":"Miedema","sequence":"additional","affiliation":[]},{"given":"Ian G.","family":"Williams","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Colebunders","sequence":"additional","affiliation":[]},{"given":"Jonathan N.","family":"Weber","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Fisher","sequence":"additional","affiliation":[]},{"given":"Roel A.","family":"Coutinho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0264-410X(02)00102-0_BIB1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/327473a0","article-title":"Prospects for the control of AIDS by immunizing seropositive individuals","volume":"327","author":"Salk","year":"1987","journal-title":"Nature"},{"issue":"10","key":"10.1016\/S0264-410X(02)00102-0_BIB2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/00002030-199310000-00003","article-title":"Immunization of human HIV-seronegative volunteers with recombinant p17\/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses","volume":"7","author":"Martin","year":"1993","journal-title":"AIDS"},{"issue":"6134","key":"10.1016\/S0264-410X(02)00102-0_BIB3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/329068a0","article-title":"The expression of hybrid HIV:Ty virus-like particles in yeast","volume":"329","author":"Adams","year":"1987","journal-title":"Nature"},{"key":"10.1016\/S0264-410X(02)00102-0_BIB4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.4049\/jimmunol.144.5.1677","article-title":"HIV p24-specific helper T-cell clones from immunized primates recognize highly conserved regions of HIV-1","volume":"144","author":"Mills","year":"1990","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/S0264-410X(02)00102-0_BIB5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0264-410X(94)00061-Q","article-title":"Immunogenicity of the yeast recombinant p17\/p24:Ty virus-like particles (p24-VLP) in healthy volunteers","volume":"13","author":"Weber","year":"1995","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/S0264-410X(02)00102-0_BIB6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/infdis\/174.4.862","article-title":"Immunization with recombinant p17\/p24:Ty virus-like particles in human immunodeficiency virus-infected persons","volume":"174","author":"Veenstra","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/S0264-410X(02)00102-0_BIB7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-4453(97)92814-0","article-title":"A pilot phase II study of the safety and immunogenicity of HIV p17\/p24:VLP (p24-VLP) in asymptomatic HIV-seropositive subjects","volume":"35","author":"Peters","year":"1997","journal-title":"J. Infect."},{"issue":"2","key":"10.1016\/S0264-410X(02)00102-0_BIB8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00002030-199802000-00007","article-title":"Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators","volume":"12","author":"Kelleher","year":"1998","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/S0264-410X(02)00102-0_BIB9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/aid.1997.13.393","article-title":"Gag-specific immune responses after immunization with p17\/p24:Ty virus-like particles in HIV type 1-seropositive individuals","volume":"13","author":"Klein","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"2","key":"10.1016\/S0264-410X(02)00102-0_BIB10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/088922299311538","article-title":"Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T-lymphocyte activity in asymptomatic HIV-infected individuals","volume":"15","author":"Benson","year":"1999","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/S0264-410X(02)00102-0_BIB11","unstructured":"Centers for Disease Control. Classification system for human T-lymphotropic virus type III\/lymphadenopathy-associated virus infections. MMWR 1986;35:334\u20139."},{"key":"10.1016\/S0264-410X(02)00102-0_BIB12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(93)93040-8","article-title":"Expanded European AIDS case definition","volume":"341","author":"Ancelle-Park","year":"1993","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/S0264-410X(02)00102-0_BIB13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJM199106133242401","article-title":"A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research","volume":"324","author":"Redfield","year":"1991","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/S0264-410X(02)00102-0_BIB14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/314587","article-title":"Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T-cell proliferative response","volume":"179","author":"Ratto-Kim","year":"1999","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/S0264-410X(02)00102-0_BIB15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00042560-199708010-00004","article-title":"Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses","volume":"15","author":"Kundu","year":"1997","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"5","key":"10.1016\/S0264-410X(02)00102-0_BIB16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002030-199805000-00008","article-title":"Phase II controlled trial of post-exposure immunization with recombinant gp 160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults","volume":"12","author":"Pontesilli","year":"1998","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/S0264-410X(02)00102-0_BIB17","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/infdis\/173.6.1336","article-title":"A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with \u2264400 CD4 T-lymphocytes\/mm3. AIDS Clinical Trials Group Protocol 137","volume":"173","author":"Valentine","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/S0264-410X(02)00102-0_BIB18","first-page":"220","article-title":"Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160","volume":"7","author":"Wahren","year":"1994","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"Suppl. 2","key":"10.1016\/S0264-410X(02)00102-0_BIB19","first-page":"S74","article-title":"Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant-controlled trial","volume":"10","author":"Trauger","year":"1995","journal-title":"J Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"issue":"5","key":"10.1016\/S0264-410X(02)00102-0_BIB20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1086\/315860","article-title":"Two double-blinded, randomized, comparative trials of four human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity. AIDS Clinical Trials Groups 209 and 214","volume":"182","author":"Schooley","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"23","key":"10.1016\/S0264-410X(02)00102-0_BIB21","doi-asserted-by":"crossref","first-page":"11204","DOI":"10.1073\/pnas.89.23.11204","article-title":"Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine","volume":"89","author":"Kundu","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/S0264-410X(02)00102-0_BIB22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/00002030-199908200-00004","article-title":"Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized","volume":"13","author":"Goebel","year":"1999","journal-title":"AIDS"},{"issue":"9041","key":"10.1016\/S0264-410X(02)00102-0_BIB23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(96)05283-X","article-title":"Randomized trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection","volume":"348","author":"Eron","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/S0264-410X(02)00102-0_BIB24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.1998.14.483","article-title":"Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency","volume":"14","author":"Tsoukas","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"3","key":"10.1016\/S0264-410X(02)00102-0_BIB25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/315308","article-title":"Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators","volume":"181","author":"Birx","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"9166","key":"10.1016\/S0264-410X(02)00102-0_BIB26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0140-6736(98)06493-9","article-title":"Therapeutic immunization with recombinant gp160 in HIV-1 infection: a randomized double-blind placebo-controlled trial. Nordic VAC-04 Study Group","volume":"353","author":"Sandstrom","year":"1999","journal-title":"Lancet"},{"issue":"19\/20","key":"10.1016\/S0264-410X(02)00102-0_BIB27","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/sim.4780131920","article-title":"The effectiveness of interventions on incubation of AIDS as measured by secular increases within a population","volume":"13","author":"Hoover","year":"1994","journal-title":"Stat. Med."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X02001020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X02001020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T06:21:58Z","timestamp":1680848518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X02001020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":27,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0264410X02001020"],"URL":"https:\/\/doi.org\/10.1016\/s0264-410x(02)00102-0","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}